UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2018
MYLAN N.V.
(Exact Name of Registrant as Specified in its Charter)
The Netherlands | 333-199861 | 98-1189497 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
Building 4, Trident Place Mosquito Way, Hatfield, Hertfordshire | AL10 9UL | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrants telephone number, including area code: +44 (0) 1707-853-000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 20, 2018, Ms. Wendy Cameron, a director of Mylan N.V. (the Company) notified the Company that she will retire from the Companys Board of Directors (the Board) effective as of the end of her term at the Companys Annual General Meeting of Shareholders (the Annual Meeting). Ms. Cameron has served on the Board for more than 16 years, including service as Chair of the Compensation Committee and on the Governance & Nominating Committee and other committees.
The Company issued a press release regarding Ms. Camerons retirement and the nomination of Ms. Pauline van der Meer Mohr as a candidate for election to the Board at the Annual Meeting which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit No. |
Description | |
99.1 | Press Release dated February 26, 2018 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MYLAN N.V. | ||||
Date: February 26, 2018 | By: | /s/ Kenneth S. Parks | ||
Kenneth S. Parks | ||||
Chief Financial Officer |
Exhibit 99.1
16-Year Veteran Director Wendy Cameron to Retire from Mylan N.V. Board after 2018 AGM
Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors
HERTFORDSHIRE, England and PITTSBURGH, February 26, 2018 /PRNewswire/ The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced that non-executive Director Wendy Cameron will retire from the Board after more than 16 years of service, effective after the 2018 Annual General Meeting of Shareholders. The Board also announced that it has nominated Pauline van der Meer Mohr as a candidate for election to Mylans Board at the 2018 Annual General Meeting.
Mylan Chairman Robert J. Coury stated, On behalf of Mylans Board of Directors, I want to express my deepest appreciation for Wendys more than 16 years of outstanding service to the Board and to all of Mylans stakeholders, including her service as Chair of the Compensation Committee and her previous service on the Governance & Nominating and other committees. Wendys leadership and significant contributions to the Board have been instrumental in helping guide Mylans strategic development, growth, and global transformation.
Mr. Coury continued, The Mylan Board has continued to refresh itself over the past decade as the Company has evolved into a leading global healthcare company, adding seven of its current eleven directors during that time frame, including four in the past five years. As the Company continues to evolve and continues the natural refreshment of its Board, we believe that Pauline represents yet another outstanding addition to the Board, given her extensive experience as a director of several multi-national companies operating in a broad range of industries, as well as her expertise in, among other areas, executive compensation, risk oversight, governance, regulatory and audit-related matters, sustainability, and talent development. I am confident that the Board and Mylans stakeholders will greatly benefit from her expertise, practical judgment, and fresh perspectives.
Ms. van der Meer Mohr is a highly respected and influential corporate leader and has significant global and Dutch company board experience. She currently is a non-executive director of HSBC Holdings plc, chairing that companys Group Remuneration (compensation) Committee and Conduct & Values Committee, and serving on its Nomination Committee. She also is a member of the supervisory boards of Royal DSM NV (currently chairing that companys Remuneration Committee and serving on its Nomination Committee), ASML Holding NV (currently serving on the Audit Committee and Selection & Nomination Committee), and EY Netherlands LLP (currently serving as Chair). In addition, she recently served as President of the Executive Board of Erasmus University in Rotterdam. Ms. van der Meer Mohr began her career in the legal profession and previously held several legal and management positions within Royal Dutch Shell Group from 1989-2004. In 2004, she was appointed group human resources director at TNT NV before becoming senior executive vice president and head of group human resources at ABN AMRO NV in 2006. She served as a member of the Dutch Banking Code Monitoring Commission in the Netherlands from 2010 to 2013, and began her own human capital consulting firm in 2008.
Ms. van der Meer Mohr said, I am honored to have been nominated for election to the Mylan N.V. Board. I have spent a great deal of time learning about the Company and meeting with the Board members and management team, and I am truly impressed by the Companys remarkable growth and success in developing such a robust and diverse global platform over a short period of time, as well as its passionate commitment to delivering on the Companys bold mission statement. I believe that Mylan has deservedly achieved its reputation as a respected leader in the global pharmaceutical industry. I am excited to have the opportunity, if elected, to use my experience to work with Mylans outstanding, dynamic Board and management team as the Company faces the challenges of an increasingly complex and changing healthcare environment and seeks to maximize opportunities for shareholders and all other stakeholders.
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do whats right, not whats easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the worlds largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.
# # #